Lazard Capital upgraded Allergen (NYSE: AGN) from Hold to Buy.

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Hot Upgrades Upgrades

Morgan Stanley Downgrades Allergen (AGN) to EqualweightMay 1, 2013 2:31 PM Allergan (AGN) Strong With or Without DARPin - RBCMay 1, 2013 12:02 PM Allergan (AGN) Says DARPin to Be Delayed, Shares Sag; Regeneron (REGN) Ramps HigherMay 1, 2013 11:26 AM Allergan (AGN) says Darpin data does not support Phase 3 trials.May 1, 2013 11:08 AM Allergan, Inc. (AGN) trading paused for volatilityMay 1, 2013 11:06 AM